![Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/7a7d5d3a-428b-4293-bccb-2be588c11397/gr1.gif)
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity
Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer
![FDA Approves Merck's KEYTRUDA® (Pembrolizumab) for First-Line Treatment of Patients with Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer, First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients - FDA Approves Merck's KEYTRUDA® (Pembrolizumab) for First-Line Treatment of Patients with Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer, First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients -](https://www.empr.com/wp-content/uploads/sites/7/2018/12/72d6c8c6fdce4a30af70a0ebc78a1feb-Keytruda-monogr.png)
FDA Approves Merck's KEYTRUDA® (Pembrolizumab) for First-Line Treatment of Patients with Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer, First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients -
![Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations](https://www.frontiersin.org/files/Articles/330851/fonc-08-00086-HTML/image_m/fonc-08-00086-g001.jpg)
Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
![Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2019/jco.2019.37.issue-7/jco.18.00149/20190216/images/large/jco.18.00149t1.jpeg)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology
![Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.[v1] | Preprints.org Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.[v1] | Preprints.org](https://www.preprints.org/img/dyn_abstract_figures/2021/07/997d10d870ce55b3615ae59f2efd8c1a/graphical.v1.png)
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.[v1] | Preprints.org
![Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/main-1249.jpg)
Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology
![The lung microenvironment: an important regulator of tumour growth and metastasis | Nature Reviews Cancer The lung microenvironment: an important regulator of tumour growth and metastasis | Nature Reviews Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41568-018-0081-9/MediaObjects/41568_2018_81_Fig1_HTML.png)
The lung microenvironment: an important regulator of tumour growth and metastasis | Nature Reviews Cancer
![Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells | Scientific Reports Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-08704-0/MediaObjects/41598_2022_8704_Fig1_HTML.png)